Dypeptidylpeptidase-4 inhibitors and the cardiovascular system: How to manage the fil rouge

Dypeptidylpeptidase-4 (DPP-4) inhibitors are a therapeutic option for improving glucose control in patients with type 2 diabetes. They can be prescribed at different stages of the natural history of the disease because of their low risk for hypoglycemia and associated weight gain. For all new drugs for diabetes, the US Food and Drug Administration requires the demonstration of the cardiovascular (CV) safety profile through pooled analyses of phase 3 studies or specifically designed trials.A significant superiority over placebo has been observed with a sodium-dependent glucose transporter-2 inhibitor, empagliflozin, and two glucagon-like peptide-1 receptor agonists, liraglutide and semaglutide, thus suggesting cardioprotective effects for some antidiabetic drugs.

Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - January 3, 2019 Category: Nutrition Authors: I. Dicembrini, M. Monami, E. Mannucci Tags: Viewpoint Source Type: research